natgillin/translations-raw huggingface dataset:
Moventig should be used with caution in these patients.
Moventig se mora primjenjivati uz oprez u tih bolesnika.
Moxidectin causes paralysis and death of nematodes and heartworms by interfering with the way signals are passed between nerve cells (neurotransmission) in the parasites’ nervous system.
Moksidektin uzrokuje paralizu i smrt nematoda i srčanih crva djelovanjem na signalne putove koji prolaze između živčanih stanica (neurotransmisija) u živčanom sustavu parazita.
Moxidectin interacts with GABA and glutamate- gated chloride channels.
Moksidektin posreduje kod gama- aminomaslačne kiseline i glutamata koji posreduju otvaranju-zatvaranju kloridnih kanala.
Moxidectin is active against larval stages of Dirofilaria immitis (L3, L4) and Dirofilaria repens (L3).
Moksidektin je učinkovit protiv larvalnih stadija Dirofilaria immitis (L3, L4) i Dirofilaria repens (L3).
Moxifloxacin (400 mg) used as a positive control showed a 5.6 msec maximum mean QTcF interval change from baseline.
Moksifloksacin (400 mg) koji se primjenjivao kao pozitivna kontrola je iskazao najveću prosječnu promjenu QTcF-intervala od 5,6 ms u odnosu na početne vrijednosti.
moxifloxacin and clarithromycin, medicines used to treat bacterial infections.
moksifloksacin i klaritromicin, lijekovi koji se koriste za liječenje bakterijskih infekcija.
moxifloxacin, sparfloxacin (see section 4.4 regarding use with other fluoroquinolones)
moksifloksacin, sparfloksacin (vidjeti dio 4.4 za primjenu s drugim fluorokinolonima)
Moxifloxacine, used to treat bacterial infections.
moksifloksacinom - koristi se za liječenje bakterijskih infekcija.
Mozobil and G-CSF
Mozobil i G-CSF
Mozobil contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium- free’.
Mozobil sadrži manje od 1 milimola natrija (23 mg) po dozi, tj. zanemarive količine natrija.
Mozobil contains sodium
Mozobil sadrži natrij
Mozobil is for subcutaneous injection.
Lijek Mozobil se primjenjuje supkutanom injekcijom.
Mozobil is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma and multiple myeloma whose cells mobilise poorly (see section 4.2).
Mozobil je u kombinaciji s čimbenikom poticanja rasta granulocita (G-CSF) indiciran za povećanje mobilizacije krvotvornih matičnih stanica u perifernu krv u svrhu prikupljanja i autologne transplantacije u odraslih bolesnika s limfomom i multiplim mijelomom iz čije se koštane srži stanice slabo mobiliziraju (vidjeti dio 4.2).
Mozobil is supplied as a clear colourless or pale yellow solution for injection in a glass vial with a non-latex rubber stopper.
Mozobil je dostupan u obliku bistre, bezbojne do blijedožute otopine za injekciju u staklenoj bočici s gumenim čepom koji ne sadrži lateks.
MP MP-T
MP-T
MPA is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase, and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA.
nekompetitivni i reverzibilan inhibitor inozin monofosfat dehidrogenaze te stoga inhibira put de novo sinteze gvanozin nukleotida bez ugradnje u DNK.
MPA’s disposition depends on several transporters.
Raspoloživost MPA ovisi o nekoliko prijenosnika.
MPS I is a heterogeneous and multisystemic disorder characterised by the deficiency of -L-iduronidase, a lysosomal hydrolase which catalyses the hydrolysis of terminal -L-iduronic residues of dermatan sulfate and heparan sulfate.
MPS I je heterogeni i multisustavni poremećaj obilježen nedostatkom α-L-iduronidaze, lizosomske hidrolaze koja katalizira hidrolizu terminalnih α-L-iduronskih ostataka dermatan sulfata i heparan sulfata.
MPS I is a rare, inherited disease, in which the level of α L iduronidase enzyme activity is much lower than normal.
MPS I je rijetka, nasljedna bolest u koje je razina aktivnosti enzima -L- iduronidaze mnogo niža od normalne.
MPS IVA is characterized by the absence or marked reduction in N-acetylgalactosamine-6-sulfatase activity.
MPS IV A je karakterizirana odsustvom ili značajnim smanjenjem aktivnosti N-acetilgalaktozamin-6-sulfataze.
MR imaging
MR oslikavanje
MRD negative
MRDnegativan
MRD negativee (%)
Negativan nalaz na MRDe (%)
MRD positive
MRDpozitivan
MRD positivef (%)
Pozitivan nalaz na MRDf (%)
MRD status at end of induction treatment
MRD status na kraju indukcijskog liječenja
MRI (0-2 years)
Magnetska rezonanca (0-2 godine)
MRI analyses used evaluable dataset.
Analize MR koristile su podatke koji su se mogli ocjenjivati.
MRI endpoints
MR ishodi
MRI endpoints
MRI ishodi
MRI Endpoints (0-2 years)
MRI ishodi (0-2 godine)
MRI endpoints#
MR ishodi#
MRI Endpointsb
Krajnje točke MRb
MRI endpoints†
MR ishodi#
MRI evaluations for T1-weighted gadolinium (Gd)-enhancing lesions and T2-hyperintense lesions were performed annually.
Magnetske rezonance za lezije T1 utvrđene gadolinijem (Gd) i za hiperintenzivne lezije T2 napravljene su jedanput godišnje.
MRI imaging may be considered as part of increased vigilance in patients considered at increased risk of PML.
MR oslikavanje može se smatrati dijelom pojačanog praćenja u bolesnika za koje se smatra da imaju povećan rizik od PML-a.
MRI Osteitis/Bone Oedema Score
MRI rezultat za osteitis/koštani edem
MRI tumour response was evaluated by RECIST 1.1. Response by digital clinical photograph was evaluated by World Health Organization (WHO) adapted criteria [partial response (PR): ≥50% decrease in the sum of the product of perpendicular diameters (SPD) of a lesion; complete response (CR): disappearance of all lesions; progressive disease: ≥25% increase in the SPD of lesions].
Tumorski odgovor na MR-u bio je procijenjen pomoću RECIST-a 1.1. Odgovor prema digitalnoj kliničkoj fotografiji bio je procijenjen prema prilagođenim kriterijima Svjetske zdravstvene organizacije (SZO) [djelomični odgovor (PR, engl. partial response): smanjenje od ≥ 50% u zbroju umnožaka najvećih okomitih promjera lezije (SPD, engl. sum of the product of perpendicular diameters); kompletan odgovor (CR, engl. complete response): nestanak svih lezija; progresivna bolest: povećanje od ≥ 25% u SPD-u lezija].
MRIs of the sacroiliac joint and spine were obtained to assess inflammation at baseline and at weeks 12 and 104.
Provedena su MR snimanja sakroilijakalnog zgloba i kralježnice kako bi se procijenila upala na početku i u 12. i 104 tjednu
MRIs of the sacroiliac joint and spine were obtained to assess inflammation at baseline and at weeks 12 and 104.
Provedena su MR snimanja sakroilijakalnog zgloba i kralježnice kako bi se procijenila upala na početku i u 12. i u 104. tjednu
MRP-2, BCRP and OATP1B1/1B3.
MRP-2, BCRP i OATP1B1/1B3.
MRT (h)
(sati)
MRT (h)
MRT (sati)
MRT (h)
Poluvije k(sati)
MS is a disease of the nerves, in which inflammation destroys the protective sheath surrounding the nerve cells.
Mulitpla skleroza je bolest živaca kod koje upala uništava zaštitnu ovojnicu živčanih stanica.
MS is a disease of the nerves, in which inflammation destroys the protective sheath surrounding the nerve cells.
Multipla skleroza bolest je živaca u kojoj upala uništava zaštitnu ovojnicu živčanih stanica.
MS is a long term illness that affects the central nervous system (CNS), including the brain and spinal cord, in which the body’s immune system (its natural defences) damages the protective layer (myelin) that surrounds the nerves in the brain and spinal cord.
MS je dugotrajna bolest koja pogađa središnji živčani sustav (SŽS), uključujući mozak i leđnu moždinu, kod koje imunološki sustav organizma (njegova prirodna obrana) oštećuje zaštitne ovojnice (mijelin) koje okružuju živčana vlakna u mozgu i leđnoj moždini.
MS is a long-term condition that affects the central nervous system (CNS), including the brain and the spinal cord.
MS je dugotrajno stanje koje utječe na središnji živčani sustav (CNS), uključujući mozak i leđnu moždinu.
MS pseudo-relapse (frequency not known): There is a possibility that at the beginning of your treatment with Rebif you may experience symptoms that resemble those of a multiple sclerosis relapse.
Simptomi nalik ponovnoj pojavi multiple skleroze (MS pseudo-relaps) (učestalost nije poznata): Postoji mogućnost da na početku liječenja Rebifom osjetite simptome koji nalikuju simptomima ponovne pojave multiple skleroze.
MS relapse
relaps multiple skleroze
MS relapse, dizziness*, hypoaesthesia, paraesthesia, tremor, dysgeusia*
relaps multiple skleroze, omaglica*, hipoestezija, parestezija, tremor, disgeuzija
MS-H Vaccine, like all vaccines, works by ‘teaching’ the immune system (the body’s natural defences) how to defend itself against a disease.
Kao i sva cjepiva, MS-H Cjepivo djeluje „učeći” imunosni sustav (prirodnu obranu tijela) kako se obraniti protiv bolesti.
MS-history yrs, median (range)
Medijan trajanja MS u godinama (raspon)
MSD Danmark ApS Tlf: +45 44 82 40 00 dkmail@merck.com
Tel.: +420 233 010 111 msd_cr@merck.com
MSD Pharma Hungary Kft Tel.: +36 1 888 5300
Tel.: +420.233.010.111
MSD Pharma Hungary Kft.
Sandoz MSD Pharma Hungariay Kft.
MSKCC prognostic score (blinded independent central review)
MSKCC prognostička ljestvica (slijepa neovisna centralna procjena)
MSWS-12-score (mean, sem) (Multiple Sclerosis Walking Scale)
MSWS-12-stupanjska ljestvica (srednja vrijednost, sem) (Ljestvica hodanja kod multiple skleroze)
MTIC is spontaneously hydrolysed to 5-amino- imidazole-4-carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTIC se spontano hidrolizira u 5-amino-imidazol-4- karboksamid (AIC), poznati međuspoj u biosintezi purina i nukleinskih kiselina te u metilhidrazin, za koji se vjeruje da je aktivan alkilirajući spoj.
MTIC is spontaneously hydrolysed to 5-amino-imidazole-4- carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTIC se spontano hidrolizira u 5-amino-imidazol-4- karboksamid (AIC), poznati međuspoj u biosintezi purina i nukleinskih kiselina te u metilhidrazin, za koji se vjeruje da je aktivan alkilirajući spoj.
MTIC is spontaneously hydrolyzed to 5-amino- imidazole-4-carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTIC se spontano hidrolizira u 5-amino-imidazol-4- karboksamid (AIC), poznati međuspoj u biosintezi purina i nukleinskih kiselina, te u metilhidrazin, za koji se vjeruje da je aktivan alkilirajući spoj.
MTIC is spontaneously hydrolyzed to 5-amino-imidazole-4- carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTIC se spontano hidrolizira u 5-amino-imidazol-4- karboksamid (AIC), poznati međuspoj u biosintezi purina i nukleinskih kiselina te u metilhidrazin, za koji se vjeruje da je aktivan alkilirajući spoj.
MTIC is spontaneously hydrolyzed to 5-amino-imidazole-4- carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTIC se spontano hidrolizira u 5-amino-imidazol-4- karboksamid (AIC), poznati međuspoj u biosintezi purina i nukleinskih kiselina, te u metilhidrazin, za koji se vjeruje da je aktivan alkilirajući spoj.
MTIC is spontaneously hydrolyzed to 5-amino-imidazole-4-carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTIC se spontano hidrolizira u 5-amino- imidazol-4-karboksamid (AIC), poznati međuspoj u biosintezi purina i nukleinskih kiselina, te u metilhidrazin, za koji se vjeruje da je aktivan alkilirajući spoj.
MTIC is spontaneously hydrolyzed to 5-amino-imidazole-4-carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTICse spontano hidrolizira u 5-amino- imidazol-4-karboksamid (AIC), poznati međuspoj u biosintezi purina i nukleinskih kiselina, te u metilhidrazin, za koji se vjeruje da je aktivan alkilirajući spoj.
MTIC is spontaneously hydrolyzed to 5amino-imidazole4carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTIC se spontano hidrolizira u 5-amino-imidazol-4- karboksamid (AIC), poznati međuspoj u biosintezi purina i nukleinskih kiselina, te u metilhidrazin, za koji se vjeruje da je aktivan alkilirajući spoj.
mTSS: modified Total Sharp Score
mTSS: modificirani ukupni rezultat po Sharpu
MTX (5 g/m2 over 24 hours, IV): day 1
MTX (5 g/m2 kroz 24 sata, i.v.): dan 1
MTX (5 g/m2 over 24 hours, IV): day 1
MTX (5 g/m² kroz 24 sata, i.v.): dan 1
MTX - Methotrexate
MTX - Metotreksat
MTX 1.5 g/m2 i.v. (24 h), day 1;
MTX 1,5 g/m2 i.v. (24 h), dan 1;
MTX 15 mg intrathecal, day 1
15 mg intratekalno, dan 1
MTX 15 mg intrathecal, day 1
MTX 15 mg intratekalno, dan 1
MTX 500 mg/m2 i.v. (24 h), days 1, 15;
MTX 500 mg/m2 i.v. (24 h), dani 1, 15;
MTX 500 mg/m2 i.v. (24 h), days 1, 15;
MTX 500 mg/m² i.v. (24 h), dani 1, 15;
MTX n=257 (95% confidence interval)
MTX n=257 (95% interval pouzdanosti
MTX n=257 (95% confidence interval)
MTX n=257 (95% interval pouzdanosti)
MTX P value
P-vrijednost
MTX-Naive
Nisu primali MTX
Muckle-Wells Syndrome (MWS)
Chronic Infantile Neurological, Cutaneous, Articular Syndrome - CINCA)
Muckle-Wells Syndrome (MWS),
Chronic Infantile Neurological, Cutaneous, Articular Syndrome - CINCA)
Muckle-Wells Syndrome (MWS),
Muckle-Wellsovog sindroma (MWS),
mucolytics and lastly, Cayston.
mukolitici i na kraju Cayston.
Mucosal healing
Cijeljenje sluznice
Mucosal healing at week 30a
Cijeljenje sluznice u
Mucosal healing at Week 30a
Cijeljenje sluznice u 30. tjednua
Mucosal healing at week 8a
Cijeljenje sluznice u 8. tjednua
Mucosal healing¶
Cijeljenje sluznice¶
Mucosal hyperplasia, with diverticulum/cyst formation was observed in the colon and caecum of mice after 2 years treatment, but this was considered a species-specific effect with no diverticula/cysts seen in long term studies in rats or dogs.
Hiperplazija sluznice s formacijom divertikula/cisti primijećena je u debelom i slijepom crijevu miševa nakon dvije godine liječenja, ali se ovo smatralo učinkom specifičnim za vrstu jer divertikuli/ciste nisu primijećeni u dugoročnim ispitivanjima kod štakora i pasa.
Mucosal inflammation
upala dojke/mastitis
Mucosal inflammation
upala sluznica
mucosal inflammation
upala sluznice
mucosal inflammation
upala sluznice,
Mucosal inflammation Fatiguew
upala sluznice umorw
Mucosal inflammation, pyrexia, weight decreased, peripheral oedema, chills
upala sluznice, pireksija, gubitak na težini, periferni edem, zimica
Mucosal inflammation, pyrexia, weight decreased, peripheral oedema, chills
upala sluznice, pireksija, gubitak na težini, periferni edem, zimica,
Mucosal inflammationa
upala sluznicaa
Mucosal inflammatione
upala sluznicee
Mucosal ulceration
ulceracije na sluznici
Mucositis or Constipation Grade 2  5 days or Grade  3 any duration1
Mukozitis ili konstipacija 2. stupnja  5 dana ili  3. stupnju bilo kojeg trajanja1
Mucositis Vomiting Diarrhoea Nausea
Mukozitis Povraćanje Proljev Mučnina
Mucositis/ stomatitis
konstipacija
Mucositis/ stomatitis
mukozitis/ stomatitis
Mucositis/ stomatitis
Vrijeme do prestanka odgovora na
Mucositis/mucosal inflammation
mukozitis/upala sluznice bol
Mucous membrane disorder
poremećaji sluznica
Muenchen Bayern, 85748 Germany
Muenchen Bayern, 85748 Njemačka
Mulhuddart Dublin 15
Mulhuddart Dublin 15 Irska
Mulhuddart Dublin 15 Ireland
Mulhuddart Dublin 15 Irska
Mulhuddart Dublin 15 Ireland.
Mulhuddart Dublin 15 Irska
Mulhuddart, Dublin 15 Ireland
Damastown Mulhuddart, Dublin 15 Irska
Mulhuddart, Dublin 15 Ireland
Mulhuddart, Dublin 15 Irska
Mulhuddart, Dublin 15, Ireland.
Damastown Mulhuddart Dublin 15 Irska
MULTAQ 400 mg film-coated tablets
MULTAQ 400 mg filmom obložene tablete
MULTAQ 400 mg tablets dronedarone
MULTAQ 400 mg tablete dronedaron
MULTAQ film-coated tablets are supplied in packs of 20, 50, 60 tablets in opaque PVC and aluminium blisters and 100x1 tablets in opaque PVC and aluminium perforated unit dose blisters.
MULTAQ filmom obložene tablete dolaze u pakiranjima od 20, 50, 60 tableta u neprozirnim PVC/ aluminij blisterima te u pakiranju sa 100x1 tabletom u neprozirnim PVC/aluminij perforiranim blisterima djeljivima na jedinične doze.
MULTAQ has no or negligible influence on the ability to drive and use machines.
MULTAQ nema ili ima zanemariv utjecaj na sposobnost upravljanja vozilima i rada sa strojevima.
MULTAQ interacts with a number of medicines; if they consult other doctors they should inform them that they are taking MULTAQ; they should not take St John’s Wort with MULTAQ; they should avoid grapefruit juice.
da se moraju obratiti liječniku ako imaju nedostatak zraka ili neproduktivan kašalj, da MULTAQ ulazi u interakcije s brojnim lijekovima te da ako odlaze drugim liječnicima, moraju im reći da uzimaju MULTAQ, ne smiju uzimati Gospinu travu s lijekom MULTAQ, moraju izbjegavati sok od grejpa.
MULTAQ is a white, oval, film-coated tablet (tablet) with a double wave marking on one side and “4142” on the other side.
MULTAQ tableta je bijela, ovalna, filmom obložena tableta (tableta) s dvostrukom valovitom oznakom na jednoj i oznakom “4142” na drugoj strani.
MULTAQ is contraindicated in patients with severe hepatic impairment because of the absence of data (see section 4.3 and 4.4).
Zbog nedostatka podataka MULTAQ je kontraindiciran u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dio 4.3 i 4.4).
MULTAQ is not recommended during pregnancy and in women of childbearing potential not using contraception.
MULTAQ se ne preporučuje tijekom trudnoće niti u žena reproduktivne dobi koje ne primjenjuju kontracepciju.
MULTAQ is not recommended if you are pregnant or you think you may be pregnant.
Ako ste trudni ili mislite da biste mogli biti trudni, ne preporučuje se primjena lijeka MULTAQ.
MULTAQ is not recommended in children and adolescents below 18 years of age.
MULTAQ se ne preporučuje za djecu i adolescente mlađe od 18 godina.
MULTAQ is used if you have a problem with your heart beat (your heart beats out of time - atrial fibrillation) and a treatment called cardioversion has changed your heartbeat back to normal rhythm.
MULTAQ se uzima ako imate tegoba s otkucajima srca (srce Vam kuca nepravilno - fibrilacija atrija) i kada je postupkom zvanim kardioverzija ponovno uspostavljen normalan ritam otkucaja srca.
MULTAQ prevents repetition of your problem of irregular heart beat.
MULTAQ sprječava ponovnu pojavu nepravilnih otkucaja srca.
multi organ dysfunction, reaction related to infusion of the medicine change in hair colour
višestruko zatajenje organa, reakcija povezana s infuzijom lijeka. promjena boje kose
multi organ inflammation
upala više organa u tijelu
Multi pack of 5 packs of 10 pre-filled syringes without needle.
Višestruko pakovanje od 5 pakovanja s 10 napunjenih štrcaljki bez igle.
Multi-dose amber glass vial containing 20 ml solution for injection, closed with a rubber stopper and sealed with an aluminium cap.
Višedozna staklena bočica žute boje koja sadrži 20 ml otopine za injekciju zatvorena gumenim čepom i aluminijskim poklopcem.
MULTI-DOSE CONTAINER
BOČICA S VIŠE DOZA
Multi-dose container:
Bočica s više doza
Multi-dose container:
Bočica s više doza:
Multi-dose vial
Višedozna bočica
Multi-dose vial
Višedozne bočice
Multi-drug resistant Mycobacterium tuberculosis (MDRH&R-TB): isolate resistant to at least isoniazid and rifampicin, but susceptible to fluoroquinolones and second line injectable agents.
Multirezistentna Mycobacterium tuberculosis (MDRH&R-TB): izolati rezistentni barem na izonijazid i rifampicin, ali osjetljivi na fluorokinolone i drugu liniju lijekova koji se primjenjuju injekcijom.
Multi-organ failure
Višestruko zatajenje organa
multi-organ failure death.
zatajenje više organa smrt.
Multi-organ failure, performance status decreased, pain, oedema, chest pain, chest discomfort, generalized oedema, face oedema, local swelling, localized oedema, weight increased, early satiety, feeling cold, injection site reaction, malaise
multiorgansko zatajenje, redukcija općeg statusa, bol, edem, bol u prsima, nelagoda u prsima, generalizirani edem, edem lica, lokalno oticanje, lokalizirani edem, povećanje težine, prerana sitost, osjećaj hladnoće, reakcija na mjestu primjene, malaksalost
multi-organ failureb,c, systemic inflammatory response syndromed, infusion related reaction
višestruko zatajenje organab,c, sindrom sistemskog upalnog odgovora, reakcije povezane s infuzijom
multi-pack
Multi-paket
Multi-pack: 12 (3 packs of 4) pre-filled pens of 0.5 ml solution.
Višestruko pakiranje: 12 (3 pakiranja s 4) napunjenih brizgalica s 0,5 ml otopine.
Multi-pack: 4 pre-filled pens of 0.5 ml solution.
Višestruko pakiranje: 4 napunjene brizgalice s 0,5 ml otopine.
Multi-packs (perforated unit dose blister) containing 98 (2 packs of 49 x 1) tablets.
Višestruka pakiranja (perforirani blisteri djeljivi na jedinične doze) sadrže 98 (2 pakiranja od 49 x 1) tableta.
Multi-packs containing 280 tablets (20 packs of 14)
Višestruka pakiranja sadrže 280 tableta (20 pakiranja od 14)
Multi-packs containing 98 tablets (2 packs of 49) and 280 tablets (20 packs of 14) Not all pack sizes or strengths may be marketed.
Višestruka pakiranja sadrže 98 tableta (2 pakiranja od 49) i 280 tableta (20 pakiranja od 14) Na tržištu se ne moraju nalaziti sve veličine pakiranja ili jačina.
Multicentre Trial N=40
Multicentrično ispitivanje N=40
multicentre, double-blind, double-dummy, parallel-group study comparing ceftazidime-
multicentričnog, dvostruko slijepog ispitivanja s dvostrukim placebom provedenog na
Multicentric Castleman’s disease causes benign tumours (non-cancerous growths) to develop in the lymph nodes in the body.
Multicentrična Castlemanova bolest uzrokuje dobroćudne tumore (nekancerozne izrasline) u limfnim čvorovima u tijelu.
Multicentric means that the disease affects several lymph nodes as well as other organs in the body.
Multicentrično znači da bolest utječe na nekoliko limfnih čvorova kao i druge organe u tijelu.
Multidose
Višedozno pakiranje
Multidose presentations must be for individual patient use only.
Višedoznu brizgalicu smije isključivo koristiti samo jedan bolesnik.
Multidose vial
Višedozna bočica
Multidose vial (10 doses of 0.5 ml)
Višedozna bočica (10 doza od 0,5 ml)
Multidose vial (5 ml)
Višedozna bočica (5 ml)
Multidose vial EU/1/09/508/009
Višedozni spremnik EU/1/09/508/009
Multidose vial:
Višedozna bočica:
Multidose.
Višedozno
Multifocal Motor Neuropathy (MMN)
Multifokalna motorička neuropatija
Multifocal motor neuropathy (MMN), a disease causing muscle weakness.
multifokalne motoričke neuropatije (MMN), bolesti koja uzrokuje slabost mišića.
Multifocal Motor Neuropathy (MMN).
Multifokalnoj motoričkoj neuropatiji (MMN).
multiforme;
sindrom; Lyellov
Multiforme†,
bulozni
multilayer polyolefin/styrene-ethylene-butylene (SEB) bag with SFC polypropylene infusion port closed with rubber stopper and snap cap.
Višeslojna poliolefin/stiren-etilen-butilen (SEB) vrećica sa SFC polipropilenskim infuzijskim otvorom zatvorenim gumenim čepom i kapicom.
multilingual blister:
multijezični blisteri:
multilingual blister:
multilijezični blisteri:
Multinational database cohort study to assess RMP specified safety outcomes in association with indacaterol/glycopyrronium bromide in Europe.
Kohortno ispitivanje s multinacionalnom bazom podataka za procjenu sigurnosnih ishoda navedenih u RMP-u povezanih s indakaterolom/glikopironijevim bromidom u Europi.
Multinucleated cells were seen in the liver in the absence of other histopathological changes in the rat carcinogenicity study.
U ispitivanju karcinogenosti u štakora primijećene su multinuklearne stanice u jetri, ali ne i druge histopatološke promjene.